New Drug Approvals (Original) — April 29, 2026

ALEMBIC received FDA biosimilar approval for FINGOLIMOD HYDROCHLORIDE (fallback type), a neutral signal offering entry into a competitive space originally dominated by Novartis' Gilenya. This positions ALEMBIC for potential share in multiple sclerosis treatment without specified designations.

The fallback approval of FINGOLIMOD HYDROCHLORIDE by ALEMBIC introduces additional pressure on originator Novartis' Gilenya, with potential for revenue erosion in the neurology/MS segment despite neutral overall signal strength.

ALEMBIC's FINGOLIMOD HYDROCHLORIDE approval heightens generic/biosimilar competition for Novartis' Gilenya in multiple sclerosis.

ALEMBIC gains FDA clearance for FINGOLIMOD HYDROCHLORIDE, enabling commercial entry as a lower-cost alternative.

{"entity"=>"ALEMBIC", "reason"=>"Fallback approval of FINGOLIMOD HYDROCHLORIDE with neutral signal and all commercial metrics NOT_DISCLOSED", "trigger"=>"product launch, initial market uptake data"}

{"entity"=>"Novartis", "reason"=>"Gilenya faces new competitive entry from ALEMBIC's FINGOLIMOD HYDROCHLORIDE", "trigger"=>"market share updates, payer coverage decisions"}